CTI Finds Pixuvri’s Conditional Authorization Is Not Enough To Win NICE Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.
You may also be interested in...
NICE On Alimta, Pixuvri Ups Concerns It Prefers Cost Over Clinical Efficacy
NICE’s tentative nod to CTI’s Pixuvri for NHL and refusal to grant an indication extension to Lilly’s Alimta could spark industry concern that the agency favors lower cost over clinical effectiveness.
CTI’s Pixuvri Flops Again At British NICE, As Discount Fails To Impress
Despite a sizeable price cut, uncertainty surrounding CTI’s non-Hodgkin’s lymphoma therapy Pixuvri has landed it with a second NICE rejection.
Germany’s G-BA Finds No Added Benefit For CTI’s Pixuvri, Exposing Price
Germany’s G-BA lets through Cell Therapeutics’ Pixuvri for aggressive B-cell non-Hodgkin's lymphoma but finds no added benefit over existing therapies, meaning its price could come under pressure.